GE builds diagnostics business with $587M Clarient buyout

GE on Friday announced plans to buy Clarient--a molecular diagnostics company with a strong focus on cancer markers--for $587 million. GE Healthcare is planning to build itself into a billion-dollar business marketing diagnostic solutions for healthcare providers. Story

Suggested Articles

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.

Autolus disclosed the departure alongside news that Nushmia Khokhar, who crossed paths with Peddareddigari at J&J, has stepped up to a SVP post.

Fauci said the FDA has vowed not to let political pressure to approve a COVID-19 vaccine as soon as possible interfere with the regulatory process.